

EXHIBIT A

Beazley, Jennalee

From: Lauren M. Lesko <LLesko@rmmslegal.com>
Sent: Tuesday, March 5, 2024 10:19 PM
To: Gregory, Teagan; M710 Team; Gordon Copland; Jamie O'Brien
Cc: Eylea; Steve Ruby; David Pogue
Subject: RE: Regeneron v. Mylan - Redactions

Teagan,

We write concerning the list of materials identified in your February 21 correspondence. While our review of those materials is ongoing, we confirm that the below-referenced documents do not contain Defendants' confidential information:

- Regeneron's Second Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 3-4) (Nov. 23, 2022)
- Regeneron's Third Set of Interrogatories to Mylan Pharmaceuticals Inc. (No. 5) (Dec. 12, 2022)
- Mylan Pharmaceuticals Inc.'s First Set of Interrogatories to Regeneron Pharmaceuticals, Inc. (Nos. 1-17) (Dec. 13, 2022)
- Mylan Pharmaceuticals Inc.'s Answers and Objections to Regeneron's Second Set of Interrogatories (Nos. 3-4) (Dec. 23, 2022)
- Mylan Pharmaceuticals Inc.'s Answers and Objections to Regeneron's Third Set of Interrogatories (No. 5) (Jan. 11, 2023)
- Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-17) (Jan. 12, 2023)
- Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant's Second Set of Interrogatories (Nos. 18-24) (Jan. 18, 2023)
- Mylan Pharmaceuticals Inc.'s First Set of Requests for Admission to Regeneron Pharmaceuticals, Inc. (Nos. 1-35) (Dec. 13, 2022)
- Regeneron Pharmaceuticals, Inc.'s Responses and Objections to Mylan Pharmaceuticals Inc.'s First Requests for Admission (Nos. 1-35) (Jan. 12, 2023)
- Transcript and exhibits from the deposition of Hanne Bak
- Transcript and exhibits from the deposition of Abby Cahn
- Transcript and exhibits from the deposition of Eric Furfine
- Transcript and exhibits from the deposition of Kenneth Graham
- Transcript and exhibits from the deposition of Amy Johnson
- Transcript and exhibits from the deposition of Shawn Lawrence
- Transcript and exhibits from the deposition of George Yancopoulos

We are available to discuss if you have any questions.

Best,
Lauren

LAUREN M. LESKO | PARTNER
LLESKO@RMMSLEGAL.COM
DIRECT | 312.222.7245
MOBILE | 630.205.2390



SIX WEST HUBBARD STREET | CHICAGO IL 60654
WWW.RMMSLEGAL.COM

This email message and any attachments are being sent by Rakoczy Molino Mazzochi Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient, please notify us immediately by replying to this message, and destroy all copies of this message and any attachments. Thank you.

From: Gregory, Teagan <TGregory@wc.com>
Sent: Tuesday, February 27, 2024 2:59 PM
To: Lauren M. Lesko <LLesko@rmmslegal.com>; M710 Team <M710Team@rmmslegal.com>; Gordon Copland <Gordon.Copland@Steptoe-Johnson.com>; Jamie O'Brien <Jamie.Obrien@Steptoe-Johnson.com>
Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
Subject: RE: Regeneron v. Mylan - Redactions

Lauren,

Do Defendants have any update on the timing of the review you indicate is underway?

Thanks,
Teagan

Teagan James Gregory
Williams & Connolly LLP
680 Maine Avenue SW, Washington, DC 20024
(P) 202-434-5178 | (F) 202-434-5029
tgregory@wc.com | www.wc.com/tgregory

From: Gregory, Teagan <TGregory@wc.com>
Sent: Friday, February 23, 2024 8:26 AM
To: Lauren M. Lesko <LLesko@rmmslegal.com>; M710 Team <M710Team@rmmslegal.com>; Gordon Copland <Gordon.Copland@Steptoe-Johnson.com>; Jamie O'Brien <Jamie.Obrien@Steptoe-Johnson.com>
Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
Subject: RE: Regeneron v. Mylan - Redactions

Lauren,

Your email was received, and we will await your further correspondence.

Teagan

From: Lauren M. Lesko <LLesko@rmmslegal.com>

To: Gregory, Teagan <TGregory@wc.com>, M710 Team <M710Team@rmmslegal.com>, Gordon Copland <Gordon.Copland@Steptoe-Johnson.com>, Jamie O'Brien <Jamie.Obrien@Steptoe-Johnson.com>
Cc: Eylea <Eylea@wc.com>, Steve Ruby <sruby@cdkrlaw.com>, David Pogue <drpogue@cdkrlaw.com>
Subject: RE: Regeneron v. Mylan - Redactions

Teagan:

A more detailed response is forthcoming – in the meantime, Biocon and Mylan do **not** consent to Regeneron producing any of the documents identified in your list below. We are endeavoring to review your requests promptly, including your newly-added requests from last night. However, Regeneron is seeking to produce documents that implicate Biocon/Mylan Confidential Information to direct competitors, and we therefore require a reasonable amount of time to carefully review your voluminous requests in order to ensure that our information is properly maintained as confidential.

Please immediately confirm that Regeneron has received this email and that Regeneron will not produce any of the below documents in “other biosimilar litigations” until we expressly authorize such production.

Best,
Lauren

LAUREN M. LESKO | PARTNER
LLESKO@RMMSLEGAL.COM
DIRECT | 312.222.7245
MOBILE | 630.205.2390



SIX WEST HUBBARD STREET | CHICAGO IL 60654
WWW.RMMSLEGAL.COM

This email message and any attachments are being sent by Rakoczy Molino Mazzocchi Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient, please notify us immediately by replying to this message, and destroy all copies of this message and any attachments. Thank you.

From: Gregory, Teagan <TGregory@wc.com>
Sent: Wednesday, February 21, 2024 9:35 PM
To: Lauren M. Lesko <LLesko@rmmslegal.com>; M710 Team <M710Team@rmmslegal.com>; Gordon Copland <Gordon.Copland@Steptoe-Johnson.com>; Jamie O'Brien <Jamie.Obrien@Steptoe-Johnson.com>
Cc: Eylea <Eylea@wc.com>; Steve Ruby <sruby@cdkrlaw.com>; David Pogue <drpogue@cdkrlaw.com>
Subject: RE: Regeneron v. Mylan - Redactions

Counsel:

Thank you for providing a redacted copy of Dr. Swartzwelder’s responsive report. I am writing now to follow up on the additional documents that I identified on January 27 and inquire about the next steps for filing redacted versions of certain docket entries pursuant to the Court’s Orders regarding the motions to intervene.

First, regarding the latter point, our last correspondence regarding unsealing/redacting certain docket entries was on January 24 when we confirmed that the Joint Motion regarding unsealing could be filed. Now that the Court has granted this Joint Motion and the identified docket entries have been unsealed, how does Mylan propose to proceed with reviewing and filing redacted versions of the remaining docket entries pursuant to the Court's Orders?

Next, on January 27 Regeneron identified the following documents it believes may contain information Defendants view as confidential. To expedite your review of these documents, as you requested, I have removed from the list the documents that we have found on the public docket or, in the case of Dr. Swartzwelder's responsive report, that you have already provided. Please either provide redacted versions or confirm that there is no Defendant confidential information in the remaining documents. Please note that pursuant to specific requests we have received, we added Mylan Pharmaceutical Inc.'s invalidity contentions to this list.

- Interrogatories and responses
 - Regeneron's Fourth Set of Interrogatories to Mylan Pharmaceuticals Inc. (Nos. 6-14) (Dec. 19, 2022)
 - Mylan Pharmaceuticals Inc.'s Answers and Objections to Regeneron's Fourth Set of Interrogatories (Nos. 6-14) (Jan. 18, 2023)
- Requests for admission and responses
 - Regeneron's First Requests for Admission to Mylan Pharmaceuticals Inc. (Nos. 1-21) (Nov. 14, 2022)
 - Mylan Pharmaceuticals Inc.'s Responses and Objections to Plaintiff's First Requests for Admission (Nos. 1-21) (Dec. 16, 2022)
 - Regeneron's Second Requests for Admission to Mylan Pharmaceuticals Inc. (Nos. 22-39) (Dec. 7, 2022)
 - Mylan Pharmaceuticals Inc.'s Responses and Objections to Regeneron's Second Requests for Admission (Nos. 22-39) (Jan. 6, 2023)
- Those portions of Defendants' Invalidity Contentions addressing US Patent Nos.:
 - 11,084,865
 - 11,104,715
- Patent dance contentions
 - Those portions of Defendants' detailed statements pursuant to 42 U.S.C. § 262(l)(3)(B) addressing US Patent Nos.:
 - 11,084,865
 - 11,104,715
 - Those portions of Regeneron's detailed statement pursuant to 42 U.S.C. § 262(l)(3)(C) addressing US Patent Nos.:
 - 11,084,865
 - 11,104,715
- Trial demonstratives
 - DDX-1 (Opening)
 - DDX-8 (MacMichael)
 - DDX-10 (MacMichael)
 - DDX-14 (Closing Infringement)
 - PDX-1 (Opening)
 - PDX-5 (Trout)
 - PDX-10 (Closing Infringement)
 - PDX-11 (Closing Validity)
- Deposition materials – transcripts and exhibits from the depositions of:
 - Richard Manning
 - Frank Swartzwelder
 - Bernhardt Trout

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.